LMY-920 for Treatment of Relapsed or Refractory Myeloma

This trial is testing a new drug called LMY-920 in people with multiple myeloma (a cancer of plasma cells in the bone marrow) whose disease has come back or stopped responding to multiple previous treatments. **You may be eligible if...** - You are 18 years or older - You have multiple myeloma that has relapsed or not responded after at least 3 prior treatment regimens, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody - Your disease is still measurable (detectable in blood, urine, or bone marrow tests) - You are in reasonably good physical condition (ECOG 0–2) **You may NOT be eligible if...** - Your myeloma has spread to your brain or spinal fluid - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding - You have an active serious infection - You have had a recent stem cell transplant Talk to your doctor to see if this trial is right for you.